Charles Morris

Company: Lava Therapeutics

Job title: Chief Medical Officer

Seminars:

Clinical Potential: GAMMABODY Platform 3:00 pm

Generating bispecific gamma delta T cell engagers that specifically activate a unique and relatively abundant effector gamma-delta T cell subset called Vγ9Vδ2 (Vgamma9 Vdelta2) T cells Complementing natural tumor recognition, direct Vγ9Vδ2 T cells to the tumor, selectively kill cancer cells and trigger an immune response cascade Demonstrating superior efficacy and safety profiles compared to…Read more

day: Conference Day Two